Genetic polymorphisms in age-related macular degeneration

A method of predicting whether a wet AMD patient has an increased likelihood of benefiting from treatment with an anti-VEGF antibody, comprising screening a sample isolated from said patient for a genomic polymorphism in the C5 complement component gene (C5) I802V allele corresponding to rs17611, wherein the patient has an increased likelihood of benefiting from said treatment if the corresponding genotype comprises AA or AG.

A method of predicting whether a wet AMD patient has an increased likelihood of benefiting from treatment with an anti-VEGF antibody, comprising screening a sample isolated from said patient for a genomic polymorphism in the HTRA1 A69S allele corresponding to rs10490924, wherein the patient has an increased likelihood of benefiting from said treatment if the corresponding genotype comprises GT.

A kit for predicting whether a wet AMD patient has an increased likelihood of benefiting from treatment with ranibizumab comprising a first oligonucleotide and a second oligonucleotides specific for a C/T polymorphism in the CFH Y402H allele corresponding to rs1061170.

A kit for predicting whether a wet AMD patient has an increased likelihood of benefiting from treatment with an anti-VEGF antibody comprising a first oligonucleotide and a second oligonucleotide specific for a A/G polymorphism in the C5 I802V allele corresponding to rs17216529.

A kit for predicting whether a wet AMD patient has an increased likelihood of benefiting from treatment with an anti-VEGF antibody comprising a first oligonucleotide and a second oligonucleotide specific for a G/T polymorphism in the HTRA1 A69S allele corresponding to rs10490924.

A method of predicting whether an individual has an increased likelihood of developing AMD, comprising screening a sample isolated from said patient for a genomic polymorphism in the C5 I145V allele corresponding to rs17216529, wherein the patient has an increased likelihood of developing AMD if the corresponding genotype comprises GG or AG.

A method of predicting whether an individual has an increased likelihood of developing wet AMD or dry with GA AMD, comprising screening a sample isolated from said patient for a genomic polymorphism in the C5 I802V allele corresponding to rs17611, wherein the patient has an increased likelihood of developing AMD if the corresponding genotype comprises allele T (ile).